Evidence map›Paper›PMID 21543337›Full record

ArticleThe Journal of biological chemistry2011

Regulation of Src family kinases involved in T cell receptor signaling by protein-tyrosine phosphatase CD148.

Ondrej Stepanek, Tomas Kalina, Peter Draber, Tereza Skopcova, Karel Svojgr, Pavla Angelisova, Vaclav Horejsi, Arthur Weiss, Tomas Brdicka

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Agonistic anti-CD148 monoclonal antibody attenuates diabetic nephropathy in mice.American journal of physiology. Renal physiology · 2020
    Article
  9. Article
  10. Review
  11. Regulation of CD4Frontiers in immunology · 2019
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Ondrej StepanekInstitute of Molecular Genetics, Academy of Sciences of Czech Republic, 142 20 Prague, Czech Republic.
Tomas Kalina
Peter Draber
Tereza Skopcova
Karel Svojgr
Pavla Angelisova
Vaclav Horejsi
Arthur Weiss
Tomas Brdicka
Czech Academy of Sciences · CZCharles University · CZCzech Academy of Sciences, Institute of Molecular Genetics · CZHoward Hughes Medical Institute · US

Funding

Function of the RPTP CD148 in the Hematopoietic LineageR01AI066120 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WEISS, ARTHUR · 2006 to 2010
$1.8M
NIAID NIH HHS AI066120NIAID NIH HHS R01 AI066120
6 · The paper itself

Abstract

CD148 is a receptor-like protein-tyrosine phosphatase known to inhibit transduction of mitogenic signals in non-hematopoietic cells. Similarly, in the hematopoietic lineage, CD148 inhibited signal transduction downstream of T cell receptor. However, it also augmented immunoreceptor signaling in B cells and macrophages via dephosphorylating C-terminal tyrosine of Src family kinases (SFK). Accordingly, endogenous CD148 compensated for the loss of the main SFK activator CD45 in murine B cells and macrophages but not in T cells. Hypothetical explanations for the difference between T cells and other leukocyte lineages include the inability of CD148 to dephosphorylate a specific set of SFKs involved in T cell activation or the lack of CD148 expression during critical stages of T cell development. Here we describe striking differences in CD148 expression between human and murine thymocyte subsets, the only unifying feature being the absence of CD148 during the positive selection when the major developmental block occurs under CD45 deficiency. Moreover, we demonstrate that similar to CD45, CD148 has both activating and inhibitory effects on the SFKs involved in TCR signaling. However, in the absence of CD45, activating effects prevail, resulting in functional complementation of CD45 deficiency in human T cell lines. Importantly, this is independent of the tyrosines in the CD148 C-terminal tail, contradicting the recently proposed phosphotyrosine displacement model as a mechanism of SFK activation by CD148. Collectively, our data suggest that differential effects of CD148 in T cells and other leukocyte subsets cannot be explained by the CD148 inability to activate T cell SFKs but rather by its dual inhibitory/activatory function and specific expression pattern.

Indexed as

Signal TransductionAdaptor Proteins, Signal TransducingAnimalsEnzyme ActivationGene Expression Regulation, EnzymologicHematopoietic Stem CellsHumansJurkat CellsLeukocyte Common AntigensMembrane ProteinsMicePhospholipase C gammaPhosphorylationProtein Structure, TertiaryReceptor-Like Protein Tyrosine Phosphatases, Class 3Receptors, Antigen, T-CellAdaptor Proteins, Signal TransducingLAT protein, humanLeukocyte Common AntigensMembrane ProteinsPhospholipase C gammaPTPRJ protein, humanReceptor-Like Protein Tyrosine Phosphatases, Class 3Receptors, Antigen, T-Cellsrc-Family KinasesTyrosine

Identifiers

PMID21543337
PMCPMC3121354
OpenAlexW1964345708

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.